Guides May 5, 2026

Cerebrolysin: Approved in 50+ Countries, Contested in Trials, and Outside the U.S. Compounding Framework

Cerebrolysin is not a single peptide. It is a porcine-brain-derived peptide mixture used in over 50 countries, backed by a large but disputed clinical literature, and awkward to place inside the normal U.S. peptide-compounding framework.

Cerebrolysin is one of the strangest compounds in the broader peptide conversation.

It has:

real international drug status
decades of published literature
use in stroke, dementia, and traumatic brain injury settings outside the United States
and a U.S. regulatory position that does not fit the normal gray-market peptide template

That combination is why people keep talking past each other about it.

Some people frame Cerebrolysin like it is just another injectable “peptide.”

Others treat its foreign approvals like proof that the clinical case is settled.

Neither framing is quite right.

What Cerebrolysin actually is

The first thing to understand is that Cerebrolysin is not a single defined peptide.

Official product materials and multiple reviews describe it as a mixture of low-molecular-weight peptides and amino acids derived from porcine brain.¹²

The Austrian prescribing information presented on the Cerebrolysin product site lists it as a solution for injection, with 215.2 mg/mL of Cerebrolysin concentrate in aqueous solution.¹

That matters because most of the compounds people discuss in peptide communities are easier to describe as:

one peptide
one sequence
one bulk active ingredient

Cerebrolysin is different.

It is better thought of as a proprietary peptide-rich biologic preparation than as a standard single-peptide API.

That structural difference drives almost every regulatory oddity that comes later.

It really is used internationally

This is not a made-up or purely gray-market product.

EVER Pharma’s own materials say Cerebrolysin is used in over 50 countries worldwide for conditions including:

ischemic and hemorrhagic stroke
traumatic brain injury
vascular dementia
Alzheimer’s disease
cognitive disorders in some markets³

The Austrian product information is a little narrower and specifically lists:

senile dementia of Alzheimer’s type
vascular dementia
stroke
craniocerebral trauma¹

So the broad international-use claim is real, but the approved labeling varies by country.

That is an important distinction.

“Approved abroad” does not mean “approved the same way everywhere.”

Why the evidence base is both substantial and disputed

Cerebrolysin is not one of those compounds where the data story is basically nonexistent.

There are randomized trials in stroke and dementia, multiple reviews, and a long-running literature spanning several indications.⁴⁵⁶⁷

At the same time, “there are many studies” is not the same thing as “the evidence is clean.”

The evidence is large, heterogeneous, and genuinely contested.

The strongest skeptical datapoint: CASTA

If you want the trial that most clearly explains the skepticism around Cerebrolysin, it is the 2012 CASTA trial in Stroke.⁴

CASTA randomized 1,070 patients with acute ischemic hemispheric stroke within 12 hours of symptom onset. Patients received either:

30 mL Cerebrolysin daily
or placebo

for 10 days, on top of aspirin.⁴

The main result was straightforward:

the confirmatory endpoint showed no significant difference between the treatment groups⁴

That is the number people need to know first.

The trial did report a post hoc signal suggesting a favorable trend in more severely affected patients, particularly those with baseline NIHSS > 12.⁴

But the correct way to frame that is:

the overall trial was neutral
the severe-stroke subgroup signal was hypothesis-generating, not definitive

That distinction matters because a lot of Cerebrolysin promotion quietly skips the first point and jumps straight to the second.

The strongest skeptical review: Cochrane 2023

The most important broad review on the stroke side is the 2023 Cochrane review on Cerebrolysin for acute ischemic stroke.²

Its conclusion was not enthusiastic.

Cochrane found moderate-certainty evidence that Cerebrolysin or similar peptide mixtures probably had no beneficial effect on preventing all-cause death after acute ischemic stroke, and it also found a potential increase in non-fatal serious adverse events with Cerebrolysin use.²

That does not mean every Cerebrolysin study is “negative.”

It does mean that when higher-level evidence synthesis looks at the stroke literature, the result is much more cautious than many Cerebrolysin fans imply.

But the literature is not only negative

This is where Cerebrolysin gets more complicated than a simple debunk.

There are also randomized studies and reviews in dementia-related populations that reported cognitive or global-function benefits, including:

a 2011 randomized trial in moderate to moderately severe Alzheimer’s disease that reported significant improvements in global clinical function and selected cognitive outcomes⁵
a 2011 randomized trial of Cerebrolysin + donepezil in Alzheimer’s disease that reported benefits across treatment groups, with combination-treatment interest remaining a live topic in the literature⁶
a Cochrane review in vascular dementia concluding Cerebrolysin may have positive effects on cognition and global function, while also stressing that the evidence was still insufficient to recommend routine treatment⁷

In other words:

the stroke evidence is mixed and frequently disappointing at the highest level
the dementia literature is more encouraging in some places, but still not decisive enough to erase the controversy

That is the honest middle ground.

Why the U.S. regulatory situation is unusually awkward

This is the part that makes Cerebrolysin stand out from the compounds that usually dominate peptide discourse.

The Cerebrolysin site’s U.S. notice is explicit:

Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.¹

So unlike many peptide substances people debate in the compounding world, Cerebrolysin is not sitting inside a familiar pattern like:

nominated to FDA bulks lists
discussed through Category 1 / 2 / 3
moving toward PCAC review

It is just outside that entire conversation.

Why the normal compounding logic does not fit cleanly

This is where the Short’s “can’t even be compounded” framing comes from, but the careful version is a little more precise.

FDA explains that under section 503A, pharmacies may compound from bulk drug substances only if those substances:

comply with an applicable USP or NF monograph;
are components of FDA-approved drug products; or
appear on FDA’s 503A bulks list.⁸

FDA gives a parallel framework for 503B outsourcing facilities, which generally requires a bulk substance on the 503B clinical-need list or use tied to the drug-shortage framework.⁹

That matters because Cerebrolysin is not being presented as:

a familiar single bulk active ingredient
a U.S.-approved drug component
or a standard nominated peptide substance in the current FDA compounding pipeline

Instead, it is a proprietary porcine-brain-derived peptide mixture marketed internationally by EVER Neuro Pharma.¹³

So the more defensible regulatory takeaway is:

Cerebrolysin does not fit cleanly into the usual U.S. pharmacy-compounding pathway the way a single nominated peptide API might.

That is a stronger and more defensible statement than pretending there is some simple one-line prohibition specific to Cerebrolysin by name.

Why this matters for people coming from the peptide world

People in peptide communities are used to thinking in categories like:

single peptide
lyophilized vial
sequence identity
third-party testing
compounding eligibility
FDA category status

Cerebrolysin does not slot neatly into that framework.

It has:

more legitimate international medical use than most gray-market peptides
more human data than most niche peptide products
but also more structural complexity and more regulatory awkwardness

That is why the conversation around it gets messy fast.

It is not just “another peptide.”

It is also not a clinically settled slam dunk.

The practical takeaway

If you want the shortest honest version, it is this:

Cerebrolysin is a porcine-brain-derived peptide mixture, not a single peptide
it is used in over 50 countries
the clinical literature is real but mixed
the biggest rigorous stroke trial, CASTA, was neutral overall
the 2023 Cochrane review was skeptical on major stroke outcomes
some dementia studies and reviews are more encouraging, but still not definitive
it is not FDA-approved in the United States
and it does not fit neatly into the standard U.S. peptide-compounding framework

That is what makes Cerebrolysin interesting.

Not because it is a simple success story.

But because it is one of the clearest examples of a peptide-based neurological product whose international use, mixed evidence, and U.S. regulatory status all pull in different directions at once.